Resources

Your selections:

Clear all

Show Filters

We found 287 resources that match your search.

Training workshop in Durban, SA supporting documents: Case Review: All About AEs - Safety Training Expedited Reporting and Assessment - Safety Training Expedited Reporting via DAERS - Safety Training Expedited reporting via DAERS - Case Study

Document Date:

Training workshop in Johannesburg, SA supporting documents: Case Review: All About AEs - Safety Training Expedited Reporting and Assessment - Safety Training Expedited Reporting via DAERS - Safety Training Expedited reporting via DAERS - Case Study

Document Date:

DAIDS sample Informed consent template, stored samples and associated health information for future research use.

Document Date:

Informed Consent documents are in the process of being updated to be compliant with the revised Common Rule.  

Document Date:

DAIDS Therapeutic Research Program protocol eligibility criteria for pregnancy prevention.

Document Date:

Document Date:

Document Date:

Document Date:

The following serious side effects have been associated with the use of darunavir given together with ritonavir (RTV). Contact your healthcare provider if you have any of the symptoms of liver problems that are listed and any skin changes with the symptoms listed below.

Document Date:

Document Date:

The following side effects have been associated with the use of didanosine:

Document Date:

Instructions for using the Table for Grading the Severity of Severity of Adult and Pediatric Adverse Events version 2.0. Changes are highlighted visually within the document.

Document Date:

Instructions for using the Table for Grading the Severity of Adult and Pediatric Adverse Events. Changes highlighted, Corrected version 2.1, July 2017

Document Date:

Instructions for using the Table for Grading the Severity of Adult and Pediatric Adverse Events. Corrected version 2.1, July 2017

Document Date:

This clarification of the DAIDS Table for Grading the Severity of Adult and Pediatric AE’s provides additional explanation of the DAIDS AE Grading Table and clarifies some of the parameters.

Document Date:

Instructions for using the Table for Grading the Severity of Severity of Adult and Pediatric Adverse Events version 2.0. This version does not visually show changes with highlighting.

Document Date:

Expedited reporting form for Adverse Events fillable using Microsoft Word.

Document Date:

Document Date:

Document Date:

Document Date:

TIVICAY is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 30 kg.

Document Date: